2. Search Result
Search Result
Pathways Recommended: TGF-beta/Smad
Results for "

TGF-βRI

" in MedChemExpress (MCE) Product Catalog:

14

Inhibitors & Agonists

1

Natural
Products

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-160215
    TGF-βRI inhibitor 1

    		TGF-β Receptor Cancer
    TGF-βRI inhibitor 1 (compoimd i) is a TGF-βRI inhibitor. TGF-βRI inhibitor 1 can be used for cancer research .
    <em>TGF-βRI</em> inhibitor 1
  • HY-160215A
    TGF-βRI inhibitor 1 methylbenzenesulfonate

    		TGF-β Receptor Cancer
    TGF-βRI inhibitor 1 (compoimd i) methylbenzenesulfonate is a TGF-βRI inhibitor. TGF-βRI inhibitor 1 methylbenzenesulfonate can be used for cancer research .
    <em>TGF-βRI</em> inhibitor 1 methylbenzenesulfonate
  • HY-114192
    TGFβRI-IN-1

    		TGF-β Receptor Cancer
    TGFβRI-IN-1 is an oral active and selective TGFβ receptor type I (TGFβRI) kinase inhibitor, with IC50 values of 2 nM and 7.6 μM for TGFβRI and TGFβRII, respectively .
    <em>TGFβRI</em>-IN-1
  • HY-161398
    TGFβRI-IN-7

    		TGF-β Receptor TGF-beta/Smad Cancer
    TGFβRI-IN-7 (Compound 2r) is a selective inhibitor of the TGFβ type II receptor (TGFβ RII) (IC50 = 4.1 μM). TGFβRI-IN-7 inhibits TGFβ signaling by promoting the proteolytic degradation of TGFβ RII. TGFβRI-IN-7 can block endothelial-to-mesenchymal transition and cell migration. TGFβRI-IN-7 can be used in cancer research .
    <em>TGFβRI</em>-IN-7
  • HY-147786
    TGFβRI-IN-5

    		TGF-β Receptor Cancer
    TGFβRI-IN-5 (Compound 4b) is a potent inhibitor of TGFβRI with an IC50 of 0.08 μM. TGFβRI-IN-5 displays amazing anticancer activity 5–7 times that of reference agent against all the tested cell lines. TGFβRI-IN-5 enhances apoptosis and arrested G2/M phase of cell cycle .
    <em>TGFβRI</em>-IN-5
  • HY-146780
    TGFβRI-IN-4

    		TGF-β Receptor Cancer
    TGFβRI-IN-4 is a highly potent and orally active TGFβ receptor type I (TGFβRI) inhibitor, with IC50s of 44 nM and 42.5 nM for ALK5 and NIH3T3. TGFβRI-IN-4 can suppress tumor growth and tumor weight in tumor xenograft model .
    <em>TGFβRI</em>-IN-4
  • HY-132290
    TGFβRI-IN-3

    		TGF-β Receptor Inflammation/Immunology Cancer
    TGFβRI-IN-3 inhibits TGFβR1 at an IC50 of 0.79 nM with 2000-fold selectivity against MAP4K4. TGFβRI-IN-3 represents a highly selective TGFβR1 inhibitor that has potential applications in immuno-oncology .
    <em>TGFβRI</em>-IN-3
  • HY-13226
    Galunisertib
    Maximum Cited Publications
    40 Publications Verification

    LY2157299

    		 TGF-β Receptor Cancer
    Galunisertib (LY2157299) is an oral and selective TGF-β receptor type I (TGF-βRI) kinase inhibitor with an IC50 of 56 nM.
    Galunisertib
  • HY-13227
    SD-208
    5+ Cited Publications

    		 TGF-β Receptor Cancer
    SD-208 is a selective TGF-βRI (ALK5) inhibitor with IC50 of 48 nM, and > 100-fold selectivity over TGF-βRII.
    SD-208
  • HY-13462
    LY-364947
    15+ Cited Publications

    HTS466284

    		 TGF-β Receptor Cancer
    LY-364947 (HTS466284) is a potent ATP-competitive inhibitor of TGFβR-I with IC50 of 59 nM, and exhibits 7-fold selectivity over TGFβR-II .
    LY-364947
  • HY-N0439
    Asiaticoside
    5+ Cited Publications

    		 TGF-beta/Smad Reactive Oxygen Species Apoptosis Endogenous Metabolite Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
    Asiaticoside, a trisaccaride triterpene from Centella asiatica, suppresses TGF-β/Smad signaling through inducing Smad7 and inhibiting TGF-βRI and TGF-βRII in keloid fibroblasts; Asiaticoside shows antioxidant, anti-inflammatory, and anti-ulcer properties.
    Asiaticoside
  • HY-144043
    ALK5-IN-8

    		TGF-β Receptor Cancer
    ALK5-IN-8 is a potent inhibitor of TGFβRI (ALK5). ALK5-IN-8 Inhibits the phosphorylation of ALK5 on its downstream signaling proteins (Smad2 or Smad3) by blocking the binding of TGFβRI to ligands, thereby affecting or blocking TGF-β signaling. ALK5-IN-8 has the potential for the research of various ALK5-mediated related diseases (extracted from patent WO2021190425A1, compound 1) .
    ALK5-IN-8
  • HY-125851
    TP-008

    		TGF-β Receptor Inflammation/Immunology
    TP-008 is a potent, selective and orally active (Activin-Like Kinase 5) ALK5 inhibitor with pIC50 and pEC50 values of 7.6 and 6.63, respectively. TGFβRI-IN-2 can produce observed cardiac toxicity in vivo at high dose .
    TP-008
  • HY-144437
    ALK5-IN-9

    		TGF-β Receptor Cancer
    ALK5-IN-9 (Compound 8h) is a potent and orally active inhibitor of TGFβRI (ALK5). ALK5-IN-9 inhibits ALK5 autophosphorylation and NIH3T3 cell activity with IC50 values of 25 nM and 74.6 nM, respectively. ALK5-IN-9 also shows favorable pharmacokinetic profile and ameliorated hERG inhibition. ALK5-IN-9 has the potential for the research of cancer disease .
    ALK5-IN-9

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: